Apellis Pharmaceuticals Inc (APLS)vsRevolution Medicines Inc (RVMD)
APLS
Apellis Pharmaceuticals Inc
$41.03
0.00%
HEALTHCARE · Cap: $5.25B
RVMD
Revolution Medicines Inc
$155.69
+3.11%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Apellis Pharmaceuticals Inc generates 148860% more annual revenue ($1.11B vs $742,000). APLS leads profitability with a 12.1% profit margin vs 0.0%. APLS earns a higher WallStSmart Score of 50/100 (C-).
APLS
Buy50
out of 100
Grade: C-
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+88.5%
Fair Value
$194.37
Current Price
$41.03
$153.34 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 33 in profit
Revenue surging 60.9% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Trading at 12.7x book value
0.0% earnings growth
Elevated debt levels
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : APLS
The strongest argument for APLS centers on Return on Equity, Revenue Growth. Revenue growth of 60.9% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : APLS
The primary concerns for APLS are P/E Ratio, Price/Book, EPS Growth.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
APLS profiles as a growth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
APLS is growing revenue faster at 60.9% — sustainability is the question.
APLS generates stronger free cash flow (-61M), providing more financial flexibility.
Bottom Line
APLS scores higher overall (50/100 vs 24/100) and 60.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Apellis Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?